Korean J Hematol.  2011 Sep;46(3):175-179. 10.5045/kjh.2011.46.3.175.

Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

• Kim JS
• Kim SJ
• Cheong JW
• Kim Y
• Hwang DY
• Yoon S
• Jang J
• Hyun SY
• Min YH

• KMID: 2252000
• DOI: http://doi.org/10.5045/kjh.2011.46.3.175

Abstract

BACKGROUND
BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand) are members of the tumor necrosis factor family and promote B cell survival and proliferation. We evaluated the correlation between serum concentration of BAFF or APRIL and severity of acute graft-versus-host disease (GVHD).
METHODS
Fifteen patients who received allogeneic hematopoietic stem transplantation for leukemia and developed acute GVHD were enrolled. We determined serum concentrations of BAFF and APRIL at the onset of the first clinical manifestation of GVHD by enzyme-linked immunosorbent assay.
RESULTS
Nine patients had grade 2 acute GVHD, and 6 had grade 3-4 acute GVHD. The BAFF serum concentration was higher in patients with grade 3-4 acute GVHD (1,093.42 in grade 2 vs. 2,171.99 pg/mL in grade 3-4), although the difference was not significant (P=0.077). However, the ratio of BAFF serum concentration to absolute lymphocyte count (ALC) (BAFF/ALC) was significantly higher in patients with grade 3-4 acute GVHD (P=0.045). The APRIL serum concentration and APRIL/ALC ratio showed similar results (P=0.077 and P=0.013, respectively).
CONCLUSION
Patients with grade 3-4 acute GVHD had higher BAFF/ALC and APRIL/ALC ratios than patients with grade 2 acute GVHD. These findings suggest that B cells might play an important role in the development of acute GVHD, and that the BAFF and APRIL concentrations in serum might be significant predictive factors for estimating the severity of acute GVHD. Their clinical significance should be further evaluated in a larger patient population.

Keyword

B cell-activating factor (BAFF); A proliferation-inducing ligand (APRIL); Acute graft-versus-host disease; Allogeneic hematopoietic stem cell transplantation

MeSH Terms

B-Lymphocytes
Cell Survival
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Humans
Leukemia
Lymphocyte Count
Transplants
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor-alpha

Reference

1. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001; 19:3685–3691. PMID: 11504750.

2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373:1550–1561. PMID: 19282026.

3. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009; 114:4919–4927. PMID: 19749094.

4. Socié G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009; 114:4327–4336. PMID: 19713461.

5. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica. 2008; 93:1702–1711. PMID: 18728020.

6. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009; 9:491–502. PMID: 19521398.

7. Yeramilli VA, Knight KL. Requirement for BAFF and APRIL during B cell development in GALT. J Immunol. 2010; 184:5527–5536. PMID: 20400696.

8. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007; 13:6107–6114. PMID: 17947475.

9. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009; 113:3865–3874. PMID: 19168788.

10. Cho BS, Min CK, Kim HJ, et al. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16:629–638. PMID: 19963070.

11. August KJ, Chiang KY, Bostick RM, et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant. 2011; 46:601–604. PMID: 20622904.

12. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997; 97:855–864. PMID: 9217189.

13. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010; 115:3861–3868. PMID: 20215642.

14. Iori AP, Torelli GF, De Propris MS, et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation. 2008; 85:386–390. PMID: 18322430.

15. Guadagnoli M, Kimberley FC, Phan U, et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood. 2011; 117:6856–6865. PMID: 21543761.